|
1
|
Chan HC and Ng SC: Emerging biologics in
inflammatory bowel disease. J Gastroenterol. 52:141–150. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Andoh A, Sakata S, Koizumi Y, Mitsuyama K,
Fujiyama Y and Benno Y: Terminal restriction fragment length
polymorphism analysis of the diversity of fecal microbiota in
patients with ulcerative colitis. Inflamm Bowel Dis. 13:955–962.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nishino K, Nishida A, Inoue R, Kawada Y,
Ohno M, Sakai S, Inatomi O, Bamba S, Sugimoto M, Kawahara M, et al:
Analysis of endoscopic brush samples identified mucosa-associated
dysbiosis in inflammatory bowel disease. J Gastroenterol.
53:95–106. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guandalini S: Update on the role of
probiotics in the therapy of pediatric inflammatory bowel disease.
Expert Rev Clin Immunol. 6:47–54. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Abdin AA and Saeid EM: An experimental
study on ulcerative colitis as a potential target for probiotic
therapy by Lactobacillus acidophilus with or without
‘olsalazine’. J Crohn's Colitis. 2:296–303. 2008. View Article : Google Scholar
|
|
6
|
Ishikawa H, Akedo I, Umesaki Y, Tanaka R,
Imaoka A and Otani T: Randomized controlled trial of the effect of
bifidobacteria-fermented milk on ulcerative colitis. J Am Coll
Nutr. 22:56–63. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kato K, Mizuno S, Umesaki Y, Ishii Y,
Sugitani M, Imaoka A, Otsuka M, Hasunuma O, Kurihara R, Iwasaki A
and Arakawa Y: Randomized placebo-controlled trial assessing the
effect of bifidobacteria-fermented milk on active ulcerative
colitis. Aliment Pharmacol Ther. 20:1133–1141. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tursi A, Brandimarte G, Giorgetti GM,
Forti G, Modeo ME and Gigliobianco A: Low-dose balsalazide plus a
high-potency probiotic preparation is more effective than
balsalazide alone or mesalazine in the treatment of acute
mild-to-moderate ulcerative colitis. Med Sci Monit. 10:PI126–PI131.
2004.PubMed/NCBI
|
|
9
|
Bibiloni R, Fedorak RN, Tannock GW, Madsen
KL, Gionchetti P, Campieri M, De Simone C and Sartor RB: VSL#3
probiotic-mixture induces remission in patients with active
ulcerative colitis. Am J Gastroenterol. 100:1539–1546. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Soo I, Madsen KL, Tejpar Q, Sydora BC,
Sherbaniuk R, Cinque B, Di Marzio L, Cifone MG, Desimone C and
Fedorak RN: VSL#3 probiotic upregulates intestinal mucosal alkaline
sphingomyelinase and reduces inflammation. Can J Gastroenterol.
22:237–242. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sood A, Midha V, Makharia GK, Ahuja V,
Singal D, Goswami P and Tandon RK: The probiotic preparation, VSL#3
induces remission in patients with mild-to-moderately active
ulcerative colitis. Clin Gastroenterol Hepatol. 7:1202–1209. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tursi A, Brandimarte G, Papa A, Giglio A,
Elisei W, Giorgetti GM, Forti G, Morini S, Hassan C, Pistoia MA, et
al: Treatment of relapsing mild-to-moderate ulcerative colitis with
the probiotic VSL#3 as adjunctive to a standard pharmaceutical
treatment: A double-blind, randomized, placebo-controlled study. Am
J Gastroenterol. 105:2218–2227. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shen J, Zuo ZX and Mao AP: Effect of
probiotics on inducing remission and maintaining therapy in
ulcerative colitis, Crohn's disease, and pouchitis: Meta-analysis
of randomized controlled trials. Inflamm Bowel Dis. 20:21–35. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nishida A, Imaeda H, Ohno M, Inatomi O,
Bamba S, Sugimoto M and Andoh A: Efficacy and safety of single
fecal microbiota transplantation for Japanese patients with mild to
moderately active ulcerative colitis. J Gastroenterol. 52:476–482.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Paramsothy S, Kamm MA, Kaakoush NO, Walsh
AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor S, Ng W,
Paramsothy R, et al: Multidonor intensive faecal microbiota
transplantation for active ulcerative colitis: A randomised
placebo-controlled trial. Lancet. 389:1218–1228. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Faith JJ, Guruge JL, Charbonneau M,
Subramanian S, Seedorf H, Goodman AL, Clemente JC, Knight R, Heath
AC, Leibel RL, et al: The long-term stability of the human gut
microbiota. Science. 341:12374392013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li SS, Zhu A, Benes V, Costea PI, Hercog
R, Hildebrand F, Huerta-Cepas J, Nieuwdorp M, Salojärvi J, Voigt
AY, et al: Durable coexistence of donor and recipient strains after
fecal microbiota transplantation. Science. 352:586–589. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nishida A, Inoue R, Inatomi O, Bamba S,
Naito Y and Andoh A: Gut microbiota in the pathogenesis of
inflammatory bowel disease. Clin J Gastroenterol. 11:1–10. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kumemura M, Saito M, Okamatsu H, Domae T
and Isono T: Survival of Pediococcus pentosaceus species in
the gastrointestinal tract and the effect of cultured vegetable
drink on fecal microflora in human. J Intestinal Microbiol.
16:139–143. 2002.
|
|
20
|
Schroeder KW, Tremaine WJ and Ilstrup DM:
Coated oral 5-aminosalicylic acid therapy for mildly to moderately
active ulcerative colitis. A randomized study. N Engl J Med.
317:1625–1629. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rachmilewitz D: Coated mesalazine
(5-aminosalicylic acid) versus sulphasalazine in the treatment of
active ulcerative colitis: A randomised trial. BMJ. 298:82–86.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dimenäs E, Glise H, Hallerbäck B,
Hernqvist H, Svedlund J and Wiklund I: Quality of life in patients
with upper gastrointestinal symptoms. An improved evaluation of
treatment regimens? Scand J Gastroenterol. 28:681–687. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Andoh A, Imaeda H, Aomatsu T, Inatomi O,
Bamba S, Sasaki M, Saito Y, Tsujikawa T and Fujiyama Y: Comparison
of the fecal microbiota profiles between ulcerative colitis and
Crohn's disease using terminal restriction fragment length
polymorphism analysis. J Gastroenterol. 46:479–486. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nagashima K, Hisada T, Sato M and
Mochizuki J: Application of new primer-enzyme combinations to
terminal restriction fragment length polymorphism profiling of
bacterial populations in human feces. Appl Environ Microbiol.
69:1251–1262. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nemoto H, Kataoka K, Ishikawa H, Ikata K,
Arimochi H, Iwasaki T, Ohnishi Y, Kuwahara T and Yasutomo K:
Reduced diversity and imbalance of fecal microbiota in patients
with ulcerative colitis. Dig Dis Sci. 57:2955–2964. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vernia P, Gnaedinger A, Hauck W and Breuer
RI: Organic anions and the diarrhea of inflammatory bowel disease.
Dig Dis Sci. 33:1353–1358. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takaishi H, Matsuki T, Nakazawa A, Takada
T, Kado S, Asahara T, Kamada N, Sakuraba A, Yajima T, Higuchi H, et
al: Imbalance in intestinal microflora constitution could be
involved in the pathogenesis of inflammatory bowel disease. Int J
Med Microbiol. 298:463–472. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Machiels K, Joossens M, Sabino J, De
Preter V, Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F,
Verbeke K, et al: A decrease of the butyrate-producing species
Roseburia hominis and Faecalibacterium prausnitzii
defines dysbiosis in patients with ulcerative colitis. Gut.
63:1275–1283. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vernia P, Caprilli R, Latella G, Barbetti
F, Magliocca FM and Cittadini M: Fecal lactate and ulcerative
colitis. Gastroenterology. 95:1564–1568. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Berlec A, Ravnikar M and Strukelj B:
Lactic acid bacteria as oral delivery systems for biomolecules.
Pharmazie. 67:891–898. 2012.PubMed/NCBI
|
